Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.65B +36.5% |
| Revenue (ttm) | 164.01M +158.0% |
| Net Income | -65.98M |
| EPS | -0.64 |
| Shares Out | 99.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,321,673 |
| Open | 27.98 |
| Previous Close | 27.93 |
| Day's Range | 26.43 - 28.75 |
| 52-Week Range | 15.35 - 36.44 |
| Beta | 2.26 |
| Analysts | Strong Buy |
| Price Target | 51.07 (+91.63%) |
| Earnings Date | May 7, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price target is $51.07, which is an increase of 91.63% from the latest price.
News
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
Bernstein analyst William Pickering lowered the firm’s price target on Beam Therapeutics (BEAM) to $39 from $40 and keeps an Outperform rating on the shares. Biotech has had a strong…
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)
Reports Q1 revenue $31.74M, consensus $12.22M. “The first quarter of 2026 was a defining period for Beam, marked by meaningful clinical advances across our portfolio and key steps toward becoming…
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort ...
Beam Therapeutics rises 10.7%
Beam Therapeutics (BEAM) is up 10.7%, or $2.90 to $30.01.
Beam Therapeutics rises 10.8%
Beam Therapeutics (BEAM) is up 10.8%, or $2.91 to $30.02.
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
Beam Therapeutics (BEAM) announced the publication of data from the ongoing Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel – risto-cel, formerly known as BEAM-101 – for the treat...
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Beam Therapeutics price target raised to $68 from $64 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Beam Therapeutics (BEAM) to $68 from $64 and keeps a Buy rating on the shares.
Clear Street sees buying opportunity for Beam Therapeutics after study update
Clear Street analyst Bill Maughan maintains a Buy rating and $37 price target on shares of Beam Therapeutics (BEAM) after the company reported Phase 1/2 data for BEAM-302 in Alpha-1…
Beam Therapeutics Transcript: Study result
BEAM-302 demonstrated robust efficacy and safety in 29 AATD patients, achieving durable, protective AAT levels and significant reduction of mutant Z-AAT with a single 60 mg dose. The therapy restored physiologic AAT regulation and showed a favorable safety profile, supporting advancement to pivotal trials.
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
Beam Therapeutics (BEAM) announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 and the selection of 60 mg as the optimal biological dose to advance…
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-u...
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
RBC Capital raised the firm’s price target on Beam Therapeutics (BEAM) to $26 from $22 and keeps a Sector Perform rating on the shares after its Q4 results. On Sickle…
Beam Therapeutics price target raised to $65 from $57 at Wedbush
Wedbush raised the firm’s price target on Beam Therapeutics (BEAM) to $65 from $57 and keeps an Outperform rating on the shares. The firm notes the company reported earnings and…
Beam Therapeutics price target raised to $75 from $74 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Beam Therapeutics (BEAM) to $75 from $74 and keeps a Buy rating on the shares. The firm said BEAM’s 4Q25…
Beam Therapeutics price target raised to $47 from $45 at BofA
BofA raised the firm’s price target on Beam Therapeutics (BEAM) to $47 from $45 and keeps a Buy rating on the shares. The firm notes Beam’s Q4 print saw updates…
Beam Therapeutics Earnings Call Transcript: Q4 2025
Expanded liver-targeted pipeline with BEAM-304 for PKU and secured $500M in non-dilutive financing to support risto-cel commercialization and pipeline growth. Strong cash position extends runway into mid-2029, with key clinical milestones ahead.
Beam Therapeutics announces $500M financing facility
Beam Therapeutics (BEAM) entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel in si...
Beam Therapeutics reports Q4 EPS $2.33 vs ($1.09) last year
“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development paths to approval across multiple ...
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Antici...
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...